Acuta Capital Partners LLC Invests $755,000 in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Acuta Capital Partners LLC acquired a new stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 740,000 shares of the biopharmaceutical company's stock, valued at approximately $755,000. Acuta Capital Partners LLC owned 0.35% of Sangamo Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SGMO. Schonfeld Strategic Advisors LLC purchased a new position in shares of Sangamo Therapeutics during the 4th quarter valued at $1,744,000. Boothbay Fund Management LLC bought a new stake in shares of Sangamo Therapeutics in the 4th quarter worth about $548,000. Golden State Equity Partners grew its stake in shares of Sangamo Therapeutics by 2,592.3% during the fourth quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company's stock worth $332,000 after acquiring an additional 313,587 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Sangamo Therapeutics by 14.6% during the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company's stock worth $1,853,000 after buying an additional 272,123 shares during the period. Finally, EAM Investors LLC purchased a new stake in shares of Sangamo Therapeutics in the 4th quarter valued at $256,000. Institutional investors own 56.93% of the company's stock.

Sangamo Therapeutics Price Performance

Shares of NASDAQ:SGMO traded down $0.00 during mid-day trading on Wednesday, reaching $0.61. 4,772,113 shares of the company were exchanged, compared to its average volume of 8,572,217. The firm has a market cap of $139.35 million, a price-to-earnings ratio of -0.81 and a beta of 1.46. The firm's 50-day simple moving average is $0.79 and its 200 day simple moving average is $1.37. Sangamo Therapeutics, Inc. has a 1 year low of $0.30 and a 1 year high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $7.55 million for the quarter, compared to analysts' expectations of $11.70 million. On average, research analysts forecast that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on SGMO. Truist Financial cut their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Sangamo Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $5.17.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.